Updates are available Correction dated 2019-07-02
Click to view Correction: https://doi.org/10.1038/s41589-019-0329-z
-
Authors
Farnaby, William http://orcid.org/0000-0001-8610-932X
Koegl, Manfred
Roy, Michael J. http://orcid.org/0000-0003-0198-9108
Whitworth, Claire http://orcid.org/0000-0003-3174-7652
Diers, Emelyne http://orcid.org/0000-0001-5951-7918
Trainor, Nicole
Zollman, David
Steurer, Steffen
Karolyi-Oezguer, Jale
Riedmueller, Carina
Gmaschitz, Teresa
Wachter, Johannes
Dank, Christian
Galant, Michael
Sharps, Bernadette
Rumpel, Klaus
Traxler, Elisabeth
Gerstberger, Thomas
Schnitzer, Renate
Petermann, Oliver
Greb, Peter
Weinstabl, Harald
Bader, Gerd
Zoephel, Andreas
Weiss-Puxbaum, Alexander
Ehrenhöfer-Wölfer, Katharina http://orcid.org/0000-0002-8893-6131
Wöhrle, Simon http://orcid.org/0000-0002-2478-7333
Boehmelt, Guido
Rinnenthal, Joerg
Arnhof, Heribert
Wiechens, Nicola
Wu, Meng-Ying
Owen-Hughes, Tom
Ettmayer, Peter http://orcid.org/0000-0002-8422-2625
Pearson, Mark
McConnell, Darryl B. http://orcid.org/0000-0002-2537-3458
Ciulli, Alessio http://orcid.org/0000-0002-8654-1670
- License Information
-
More Information
Article History
Received: 14 August 2018
Accepted: 16 April 2019
First Online: 10 June 2019
Change Date: 2 July 2019
Change Type: Correction
Change Details: In the version of this article originally published, several lines of text in the last paragraph of the right column on page 1 of the PDF were transposed into the bottom paragraph of the left column. The affected text of the left column should read “The ATP-dependent activities of the BAF (SWI/SNF) chromatin remodeling complexes affect the positioning of nucleosomes on DNA and thereby many cellular processes related to chromatin structure, including transcription, DNA repair and decatenation of chromosomes during mitosis<sup>12,13</sup>.” The affected text of the right column should read “SMARCA2/4<sup>BD</sup> inhibitors are thus precluded from use for the treatment of SMARCA4 mutant cancers but could provide attractive ligands for PROTAC conjugation. Small molecules binding to other bromodomains have been successfully converted into PROTACs by conjugating them with structures capable of binding to the E3 ligases von Hippel−Lindau (VHL) or cereblon<sup>5,6,10,11,25,26,27</sup>.” The errors have been corrected in the PDF version of the paper.
Competing interests
: A.C. is a scientific founder, director and shareholder of Amphista Therapeutics, a company that is developing targeted protein degradation therapeutic platforms.
